OrthoPediatrics (KIDS) Expected to Announce Earnings on Tuesday

OrthoPediatrics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • OrthoPediatrics is expected to report Q3 2026 earnings after the market closes on October 27. Analysts forecast a loss of $0.225 per share and revenue of $68.50 million.
  • In its previous quarter, the company reported a narrower-than-expected loss of $0.26 per share and revenue of $70.51 million, exceeding consensus estimates. Analysts expect full-year and next-year losses of $1.14 and $0.83 per share, respectively.
  • Analyst sentiment remains favorable, with a “Moderate Buy” consensus rating and a $26.50 target price, although insiders sold approximately $46.7 million of stock over the past quarter.
  • Five stocks to consider instead of OrthoPediatrics.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) will likely be issuing its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect OrthoPediatrics to announce earnings of ($0.2250) per share and revenue of $68.50 million for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, October 27, 2026 at 4:30 PM ET.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. The firm had revenue of $70.51 million for the quarter, compared to analysts' expectations of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. On average, analysts expect OrthoPediatrics to post ($1.14) EPS for the current fiscal year and ($0.83) EPS for the next fiscal year.

OrthoPediatrics Stock Performance

OrthoPediatrics stock opened at $22.03 on Tuesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17. The stock has a fifty day moving average of $23.06 and a two-hundred day moving average of $20.00. OrthoPediatrics has a fifty-two week low of $14.42 and a fifty-two week high of $26.74.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on KIDS shares. Weiss Ratings upgraded OrthoPediatrics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, August 5th. Piper Sandler reissued an "overweight" rating and issued a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. BTIG Research reissued a "buy" rating and issued a $29.00 target price on shares of OrthoPediatrics in a research note on Monday, September 14th. Needham & Company LLC upped their target price on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Finally, Truist Financial raised shares of OrthoPediatrics to a "hold" rating in a research note on Thursday, October 1st. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, OrthoPediatrics currently has a consensus rating of "Moderate Buy" and a consensus target price of $26.50.

Get Our Latest Analysis on KIDS

Insider Transactions at OrthoPediatrics

In other news, Director David Pelizzon sold 302,369 shares of the firm's stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the sale, the director owned 6,201,764 shares in the company, valued at $130,299,061.64. This trade represents a 4.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Jennifer Pritzker sold 302,369 shares of OrthoPediatrics stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the sale, the insider directly owned 6,201,764 shares of the company's stock, valued at approximately $130,299,061.64. This represents a 4.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 2,100,000 shares of company stock worth $46,747,931 over the last quarter. 32.50% of the stock is currently owned by insiders.

OrthoPediatrics Company Profile

(Get Free Report)

OrthoPediatrics Corp. is a medical device company focused exclusively on developing and commercializing orthopedic products for children. Headquartered in Warsaw, Indiana, the company designs implants and instruments intended to address the distinct anatomical and clinical needs of pediatric patients, including those whose bones are still growing.

Its product portfolio includes systems for pediatric trauma and deformity correction, scoliosis treatment, limb reconstruction, and pediatric sports medicine.

Featured Stories

Earnings History for OrthoPediatrics (NASDAQ:KIDS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in OrthoPediatrics Right Now?

Before you consider OrthoPediatrics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OrthoPediatrics wasn't on the list.

While OrthoPediatrics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines